• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ACOR

    Acorda Therapeutics Inc.

    Subscribe to $ACOR
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

    IPO Year: 2006

    Exchange: NASDAQ

    Website: acorda.com

    Peers

    $FOLD
    $SRPT

    Recent Analyst Ratings for Acorda Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Acorda Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Acorda Therapeutics upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Acorda Therapeutics from Neutral to Buy and set a new price target of $10.00 from $5.00 previously

      6/17/21 6:09:07 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Acorda Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Burns Thomas M.

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 7:59:21 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Burns Thomas M.

      3 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 7:57:11 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Varian John

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 5:38:37 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Panem Sandra Phd

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 5:37:30 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Kelley John P

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 5:36:22 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Jensen Peder

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 5:34:24 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Cohen Ron

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      4/4/23 4:42:10 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Clem Kerry M

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      4/4/23 4:40:33 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Belloff Neil S.

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      4/4/23 4:38:58 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Acorda Therapeutics Inc.

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      3/20/23 4:29:58 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care